Comparison 4.
Propranolol versus other drugs
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Responders (parallel‐group and 1st period crossover data) | 5 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 1.1 Propranolol 160 mg vs. femoxetine 400 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 1.2 Propranolol 120‐160 mg vs. cyclandelate 1200‐1600 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 1.3 Propranolol 120 mg vs. cyclandelate 1200 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 1.4 Propranolol 60‐240 mg vs. divalproex sodium 1000‐2000 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 1.5 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2 Responders (parallel‐group and pooled crossover data [one 1st period]) | 10 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 2.1 Propranolol 160 mg vs. femoxetine 400 mg | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.2 Propranolol 120‐160 mg vs. cyclandelate 1200‐1600 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.3 Propranolol 120 mg vs. cyclandelate 1200 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.4 Propranolol 60‐240 mg vs. divalproex sodium 1000‐2000 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.5 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.6 Propranolol 120 mg vs. methysergide 3 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.7 Propranolol 160 mg vs. clonidine 100 mcg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.8 Propranolol 80‐240 mg vs. amitriptyline 50‐150 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 2.9 Propranolol 1.8 mg/kg vs. ASA 13.5 mg/kg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 3 Attack frequency measures (parallel‐group and 1st period crossover data) | 8 | Std. Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 3.1 Propranolol 160 mg vs. femoxetine 400 mg | 2 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 3.2 Propranolol 120 mg vs. tolfenamic acid 300 mg | 2 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 3.3 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 3.4 Propranolol 120 mg vs. naproxen 1100 mg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 3.5 Propranolol 1230 mcg/kg vs. methysergide 30.8 mcg/kg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 3.6 Propranolol 80 mg vs. alpha‐dihydroergocryptine 20 mg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4 Attack frequency measures (parallel‐group and pooled crossover data [two 1st period]) | 10 | Std. Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 4.1 Propranolol 160 mg vs. femoxetine 400 mg | 2 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.2 Propranolol 120 mg vs. tolfenamic acid 300 mg | 2 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.3 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.4 Propranolol 120 mg vs. naproxen 1100 mg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.5 Propranolol 1230 mcg/kg vs. methysergide 30.8 mcg/kg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.6 Propranolol 240 mg vs. mefenamic acid 1500 mg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.7 Propranolol 160 mg vs. clonidine 100 mcg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.8 Propranolol 80 mg vs. alpha‐dihydroergocryptine 20 mg | 1 | Std. Mean Difference (IV, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 5 Number of patients with adverse events (parallel‐group; no 1st period crossover data) | 4 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 5.1 Propranolol 120‐160 mg vs. cyclandelate 1200‐1600 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 5.2 Propranolol 120 mg vs. cyclandelate 1200 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 5.3 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 5.4 Propranolol 120 mg vs. naproxen 1100 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6 Number of patients with adverse events (parallel‐group and pooled crossover data) | 10 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 6.1 Propranolol 120‐160 mg vs. cyclandelate 1200‐1600 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.2 Propranolol 120 mg vs. cyclandelate 1200 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.3 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.4 Propranolol 120 mg vs. naproxen 1100 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.5 Propranolol 120 mg vs. tolfenamic acid 300 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.6 Propranolol 120 mg vs. methysergide 3 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.7 Propranolol 160 mg vs. clonidine 100 mcg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.8 Propranolol 60‐240 mg vs. divalproex sodium 1000‐2000 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.9 Propranolol 1.8 mg/kg vs. ASA 13.5 mg/kg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 6.10 Propranolol 240 mg vs. mefenamic acid 1500 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7 Number of dropouts due to adverse events (parallel‐group; no 1st period crossover data) | 5 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 7.1 Propranolol 120 mg vs. cyclandelate 1200 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7.2 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7.3 Propranolol 160 mg vs. dihydroergotamine 10 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7.4 Propranolol 120‐160 mg vs. amitriptyline 50‐75 mg | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7.5 Propranolol 120‐160 mg vs. amitriptyline 50‐75 mg + propranolol 120‐160 mg | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8 Number of dropouts due to adverse events (parallel‐group and pooled crossover data) | 16 | Risk Ratio (M‐H, Fixed, 95% CI) | Totals not selected | |
| 8.1 Propranolol 160 mg vs. femoxetine 400 mg | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.2 Propranolol 120 mg vs. cyclandelate 1200 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.3 Propranolol 80‐240 mg vs. divalproex sodium 750‐1500 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.4 Propranolol 60‐240 mg vs. divalproex sodium 1000‐2000 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.5 Propranolol 120 mg vs. 5‐hydroxytryptophan 300 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.6 Propranolol 240 mg vs. mefenamic acid 1500 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.7 Propranolol 120 mg vs. tolfenamic acid 300 mg | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.8 Propranolol 120 mg vs. methysergide 3 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.9 Propranolol 160 mg vs. dihydroergotamine 10 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.10 Propranolol 80 mg vs. alpha‐dihydroergocryptine 20 mg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.11 Propranolol 160 mg vs. clonidine 100 mcg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.12 Propranolol 1.8 mg/kg vs. ASA 13.5 mg/kg | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.13 Propranolol 120‐160 mg vs. amitriptyline 50‐75 mg | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8.14 Propranolol 120‐160 mg vs. amitriptyline 50‐75 mg + propranolol 120‐160 mg | 2 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.0 [0.0, 0.0] |